We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-8.24%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.72B
AUM Growth
-$153M
Cap. Flow
+$152M
Cap. Flow %
8.83%
Top 10 Hldgs %
73.79%
Holding
30
New
4
Increased
9
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
THOR
Synthorx, Inc. Common Stock
THOR
+$141M
2
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$72.2M
3
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$26M
4
MRNA icon
Moderna
MRNA
+$24.9M
5
ZGNX
Zogenix, Inc.
ZGNX
+$20.6M

Top Sells

Rank Stock Value
1
ECYT
Endocyte, Inc. Common Stock
ECYT
+$110M
2
SAGE
Sage Therapeutics
SAGE
+$49.6M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$19.4M
4
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$19M
5
APLS
Apellis Pharmaceuticals
APLS
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 95.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
26
DELISTED
Apellis Pharmaceuticals
APLS
– –
-900,000
Closed -$16M
CBIO
27
Crescent Biopharma
CBIO
$546M
– –
-2,535
Closed -$3.65M
SAGE
28
DELISTED
Sage Therapeutics
SAGE
– –
-350,933
Closed -$49.6M
PGNX
29
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-3,030,303
Closed -$19M
ECYT
30
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-6,196,143
Closed -$110M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, RA Capital Management held 30 positions worth $1.72B, down 8.2% from $1.87B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

RA Capital Management deployed $152M of net new capital in Q4 2018, opening 4 new positions and adding to 9 existing holdings. Its largest new stake was Synthorx, Inc. Common Stock: 9,724,598 shares worth $169M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Dicerna Pharmaceuticals, Inc., an estimated $19.4M trimmed.

  • RA Capital Management's largest Q4 2018 buy was Synthorx, Inc. Common Stock: 9,724,598 shares worth $169M.
  • RA Capital Management added most to Zogenix, Inc. in Q4 2018, an estimated $20.6M increase.
  • RA Capital Management's biggest Q4 2018 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $19.4M.
  • RA Capital Management fully exited Endocyte, Inc. Common Stock in Q4 2018, selling an estimated $110M.
  • RA Capital Management's ten largest holdings make up 74% of its $1.72B portfolio in Q4 2018.
  • RA Capital Management opened 4 new positions and closed 5 in Q4 2018.
  • RA Capital Management's portfolio value fell 8.2% quarter-over-quarter to $1.72B.

Based on RA Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.